Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Study sponsor: Abivax S.A. · ABVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-12Estimated
Enrollment · participants212Estimated
Source updated2026-04-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.